Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
J ANTIINFECTIVES FOR SYSTEMIC USE
J05 ANTIVIRALS FOR SYSTEMIC USE
J05A DIRECT ACTING ANTIVIRALS
J05AE Protease inhibitors
J05AE30 Nirmatrelvir and ritonavir
D12269 Nirmatrelvir and ritonavir <JP/US>
USP drug classification [BR:br08302]
Antivirals
Antivirals, Coronavirus Agents
Nirmatrelvir/ Ritonavir
D12269 Nirmatrelvir and ritonavir
Therapeutic category of drugs in Japan [BR:br08301]
6 Agents against pathologic organisms and parasites
62 Chemotherapeutics
625 Antivirals
6250 Antivirals
D12269 Nirmatrelvir and ritonavir
Drug groups [BR:br08330]
Antiviral
DG03174 Anti-SARS-CoV-2 agent
D12269 Nirmatrelvir and ritonavir
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
D12269 Nirmatrelvir and ritonavir
Metabolizing enzyme inhibitor
DG02852 CYP3A/CYP3A4 inhibitor
D12269 Nirmatrelvir and ritonavir
Drug classes [BR:br08332]
Antiviral
DG03174 Anti-SARS-CoV-2 agent
D12269 Nirmatrelvir and ritonavir
Antimicrobials [BR:br08307]
Antivirals
Polyprotein cleavage inhibitor
SARS-CoV 3C protease inhibitor
D12269 Nirmatrelvir and ritonavir <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D12269
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D12269
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D12269
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D12269
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D12269
